| Products/Services Used | Details | Operation |
|---|---|---|
| Gene Synthesis | The mouse C5 protein sequence was analyzed using OptimumAntigen Design software (Genscript, NJ), which utilizes an advanced antigen design algorithm based on several protein databases. The identified epitopes were compared with the published C5 protein crystal structure27 to check for surface exposure. These steps provided 12 potential immunogenic epitopes that are likely present on the surface of the native mouse protein. An artificial gene was designed coding for a polypeptide comprised of these 12 potential epitopes interspersed in three places with a copy of the nonnatural pan-DR epitope (PADRE) sequence (a linear peptide that improves humoral responses against antigens and helps break immune tolerance25,26) and capped at the C-terminus with a 6XHis tag. | Get A Quote |
The complement system is emerging as a new target for treating many diseases. For example, Eculizumab, a humanized monoclonal antibody against complement component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) in which patient erythrocytes are lysed by complement. In this study, we developed vaccines to elicit autologous anti-C5 antibody production in mice for complement inhibition. Immunization of mice with a conservative C5 xenoprotein raised high titers of IgG’s against the xenogenous C5, but these antibodies did not reduce C5 activity in the blood. In contrast, an autologous mouse C5 vaccine containing multiple predicted epitopes together with a tolerance-breaking peptide was fou... More
